ABM posts mixed second-quarter fiscal 2025 results as earnings fall short of estimates but revenues beat, with segment growth led by aviation and tech solutions.

CG is set to collaborate with C to expand fintech-focused asset-backed finance through a new strategic alliance.

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.

Stantec (STN) could produce exceptional returns because of its solid growth attributes.

New Jersey Resources (NJR) could produce exceptional returns because of its solid growth attributes.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153345&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.

Permian Resources continues to deliver rare growth through strategic, accretive acquisitions. Management's disciplined approach—favoring multiple small, value-accretive deals over large, costly ones—minimizes risk and maximizes upside. The company boasts top-tier acreage and a fortress balance sheet.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / WHY: New York, N.Y., June 16, 2025.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ:WOOF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Dan Ives, Wedbush Securities, joins CNBC's Dom Chu on ‘Halftime Report' to discuss his new AI revolution ETF, the top holdings and how it stands out from the competition.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Rocket Companies, Inc. (NYSE:RKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=153344&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

SKYT rebounds with a 70% jump in Wafer Services revenues as its ThermaView platform gains rapid traction in defense.

SkyWater Technology's quantum push, Fab 25 deal and lean valuation stack up strongly against Marvell Technology's AI-fueled momentum.

Shares of EchoStar rose as much as 50% on Monday following a late Friday Bloomberg report that U.S. President Donald Trump urged EchoStar Chairman Charlie Ergen and Federal Communications Commission Chair Brendan Carr to reach a deal over the fate of the company's wireless spectrum licenses.

Gold is losing ground as traders take some profits off the table despite tensions in the Middle East.

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=153343&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.